Stemline Therapeutics
Stemline Therapeutics, Inc..
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $677m Valuation: $677m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Stemline Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and delivering transformative therapies for oncology patients. The company focuses on creating a broad pipeline of innovative treatments aimed at improving the lives of individuals battling cancer. Stemline serves patients, healthcare providers, and the broader medical community, operating primarily in the oncology market. The business model revolves around extensive research and development, clinical trials, and the commercialization of its proprietary therapies. Revenue is generated through the sale of these therapies, partnerships, and licensing agreements. Stemline leverages its scientific leadership and commercial expertise to bring cutting-edge treatments to market, addressing unmet medical needs in cancer care.
Keywords: biopharmaceutical, oncology, cancer, innovative therapies, clinical trials, scientific leadership, commercial expertise, transformative treatments, healthcare, research and development.